N/A
N=23
Spinal Plasticity to Enhance Motor Retraining After Stroke
Stroke · Cerebrovascular Accident · Hemiparesis
Bottom Line
View on ClinicalTrials.gov: NCT03645122 ↗Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Motor Control & Learning — 0.339; 0.359; 0.301 Newton
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Paired corticospinal-motoneuronal stimulation (PCMS) (Other); Sham stimulation (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Sep 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Motor Control & Learning |
0.339; 0.359; 0.301 | — |
Summary
The objective of this project is to study the effects of an emerging noninvasive neuromodulation strategy in human stroke survivors with movement-related disability. Muscle weakness after stroke results from the abnormal interaction between cells in the brain that send commands to control movement and cells in the spinal cord that cause muscles to produce movement. The neuromodulation strategy central to this project has been shown the strengthen the physical connection between both cells, producing a change in movement potential of muscles weakened by stroke.
Eligibility Criteria
Inclusion Criteria
- Between the ages of 18 and 75 years old
- Diagnosis of first-ever stroke
- Stroke onset of at least six months prior to the time of participation
Exclusion Criteria
- History of seizure or epilepsy
- Ferromagnetic metallic implants, pacemakers, other implanted devices, or ventilators (for subjects undergoing MRI)
- Pregnant or expecting to become pregnant
- Difficulty maintaining alertness and/or remaining still
- Body weight > 300 lbs due to MRI scanner dimensions (for subjects undergoing MRI)
- Cognitive or language impairments that would interfere with the ability to follow simple instructions, as judged by the investigators
- Diagnosis of movement disorder(s) other than stroke
Data sourced from ClinicalTrials.gov (NCT03645122). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.